5 medical device companies to watch in 2013, according to the new 2013 Frost & Sullivan outlook projections for the global medical device market.
The Research identifies market sectors and sub-sectors poised for expansion; discusses key opportunities in emerging markets; identifies the four Rs in the medical device spectrum; and covers strategies for success in the new market paradigm.
2013 marks the beginning of a new era in the medical device market that is more sensitive to the value of care with the report also predicting the launch of health exchanges and rollbacks in employer-covered plans could lead to more distinct tiers of coverage. Medical device companies will also find it increasingly difficult to invest in emerging market strategies.
2013 Frost & Sullivan outlook study also identified the 5 medical device companies to watch in 2013 and why.
1. Johnson & Johnson
Major restructuring of the company in 2012 introduced a new CEO and the consolidation of multiple device franchises into three units. Aggressive portfolio management is expected in 2013 as it sheds sluggish businesses and enters into new markets via acquisitions.
Medtronic’s 2012 Kanghui acquisition exemplifies the emphasis of emerging markets in the company’s long term vision. In the US, expected 2013 approvals for transcatheter and renal denervation technologies would provide access to two hot-growth treatments.
In early 2013, Stryker announced acquisition of a Chinese orthopedic implant developer. Value-based devices and access to emerging markets are increasingly driving industry M&A activity. Stryker is also expected to make a play in robot assisted surgery as well.
Covidien has been steadily building its portfolio of products via acquisitions to transition from commoditized markets to those with significant growth potential. Now that it has established a presence, the company is expected to be much more aggressive in capturing share.
5. St. Jude Medical
While St. Jude Medical faces weakening sales for its core markets of pacemakers, ICDs, and artificial heart valves, it is well-positioned in the hot-growth markets of transcatheter valves, fractional flow reserve (FFR) testing, cardiac ablation, neuromodulation, and renal denervation.
Latest posts by Jasmine Pennic (see all)
- CMS Proposes Stage 2 and 3 Meaningful Use Extension - December 6, 2013
- Cerner Partners With Claritas Genomics to Accelerate Personalized Medicine - December 5, 2013
- 2 Roadblocks to the Realization of Big Data in Healthcare - December 5, 2013